Tarlatamab Maintenance Therapy Extends Overall Survival in Advanced Small-Cell Lung Cancer to Nearly 2 Years
Source Summary
A large randomized trial demonstrated that tarlatamab (Imdelltra) combination maintenance therapy following first-line chemoimmunotherapy achieved median overall survival approaching 2 years in extensive-stage small-cell lung cancer. This represents a significant clinical outcome in a disease with historically poor prognosis.
Why it matters
Extended overall survival in extensive-stage small-cell lung cancer, historically one of the most aggressive malignancies, represents a meaningful clinical advance for patients with limited treatment options.
